Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform
Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization
Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test
Co-Diagnostics announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAPLEX™ Flu A/Flu B/COVID-19 (ABC) RT-PCR test as an in vitro diagnostic (IVD).
Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant
None of the mutations in the Omicron variant interfere with any of the Company’s COVID-19 PCR diagnostic assays
Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results
Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38
Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom
Company’s validated test available in the UK following implementation of UKHSA CTDA Regulations
Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28
In addition to hosting a booth to promote its existing diagnostics products at the conference, the Company will also hold a press conference to introduce its upcoming at-home and point-of-care PCR device.
Co-Diagnostics, Inc. Announces Corporate Rebranding Following Period of Transformative Growth and Expansion
Co-Diagnostics, Inc. announced that following its recent transformative growth, the Company is rebranding its image to better reflect its expanded scope, mission, and upcoming expansion into new diagnostics verticals.
Co-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference
On September 13th, Co-Diagnostics, Inc. announced that Company CEO Dwight Egan will participate in a panel discussion hosted by Scott Gottlieb, M.D., titled “How We Can Defeat the Next Pandemic” at the H.C. Wainwright & Co. 2021 Global Investor Conference, being held virtually on September 13-15, 2021.
Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy
Peer-reviewed results describe the Company’s test being used to confirm the presence of the virus on community waste, including mutated strains
